This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 52.9 kDa. The protein migrates as 57-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.0. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human LILRB4, Fc Tag (SPR verified) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Human LILRB4, Fc Tag (SPR verified) (Cat. No. LI4-H5259) captured on CM5 chip via anti-human IgG Fc antibodies surface can bind Human ANGPTL7, His tag (Cat. No. AN7-H52H5) with an affinity constant of 71.6 nM as determined in a SPR assay (Biacore T200) (QC tested).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $350.00
Price(USD) : $2200.00
ACROBiosystems has developed a series of critical reagents for COVID-19 vaccine development and evaluation,including proteins, antibodies and kits. These featured products are suitable for IgG/M antibody titer detection, neutralizing antibody titer detection and antigen titer detection.
High quality SARS-CoV-2 S protein, S1 protein and human ACE2 protein based on the human cell expression platform of HEK293.
ACROBiosystems has developed a serial of high-quality antigen and antibody reagents, including super stable trimeric S protein, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity verified by inactivated virus samples.
ACROBiosystems has developed a series of kit products using its high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.
This web search service is supported by Google Inc.